Roche Enters Licensing Agreement With Sarepta Therapeutics for Gene Therapy
December 23 2019 - 2:25AM
Dow Jones News
By Cristina Roca
Roche Holding AG (RO.EB) said Monday that it has struck a
licensing deal with Sarepta Therapeutics Inc. (SRPT) for the
exclusive right to launch and commercialize a gene therapy used for
patients with Duchenne muscular dystrophy outside the U.S.
The Swiss pharmaceutical company said it will pay Sarepta an
upfront $750 million in cash and $400 million in equity at closing,
which is expected in the first quarter of 2020, for the rights to
its SRP-9001 investigational gene therapy.
Sarepta is also eligible to receive regulatory and sales
milestones of up to $1.7 billion, plus royalties on net sales,
Roche said. The two companies will also share global development
expenses.
Write to Cristina Roca at cristina.roca@dowjones.com
(END) Dow Jones Newswires
December 23, 2019 02:10 ET (07:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2023 to Sep 2024